[{"id":"6a99cbf8-fa32-41bd-b75c-bb2ad00c230c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03921879","created_at":"2021-01-18T19:17:44.135Z","updated_at":"2024-07-02T16:36:39.692Z","phase":"Phase 1","brief_title":"Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma","source_id_and_acronym":"NCT03921879","lead_sponsor":"Oncotartis, Inc.","biomarkers":" NAMPT","pipe":"","alterations":" ","tags":["NAMPT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OT-82"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/29/2019","start_date":" 07/29/2019","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2020-10-23"}]